Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice

NCT07663786 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

726

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Adenocarcinoma
Gastro-esophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions

DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb